![]() |
Name |
Cerrenin B
|
Molecular Formula | C15H22O3 | |
IUPAC Name* |
(1S,3bS,6aR,7S,7aS)-3b,7-dihydroxy-1,5,5,7a-tetramethyl-4,6,6a,7-tetrahydro-1H-cyclopenta[a]pentalen-2-one
|
|
SMILES |
C[C@@H]1C(=O)C=C2[C@]1([C@H]([C@@H]3[C@]2(CC(C3)(C)C)O)O)C
|
|
InChI |
InChI=1S/C15H22O3/c1-8-10(16)5-11-14(8,4)12(17)9-6-13(2,3)7-15(9,11)18/h5,8-9,12,17-18H,6-7H2,1-4H3/t8-,9-,12+,14+,15+/m1/s1
|
|
InChIKey |
PHZRVCXTBKNJFU-NHYBKEFLSA-N
|
|
Synonyms |
Cerrenin B
|
|
CAS | NA | |
PubChem CID | 146684386 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 250.33 | ALogp: | 1.1 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 57.5 | Aromatic Rings: | 3 |
Heavy Atoms: | 18 | QED Weighted: | 0.693 |
Caco-2 Permeability: | -4.791 | MDCK Permeability: | 0.00003790 |
Pgp-inhibitor: | 0.038 | Pgp-substrate: | 0.429 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.923 | Plasma Protein Binding (PPB): | 69.59% |
Volume Distribution (VD): | 1.203 | Fu: | 29.70% |
CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.908 |
CYP2C19-inhibitor: | 0.065 | CYP2C19-substrate: | 0.813 |
CYP2C9-inhibitor: | 0.026 | CYP2C9-substrate: | 0.108 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.097 |
CYP3A4-inhibitor: | 0.085 | CYP3A4-substrate: | 0.41 |
Clearance (CL): | 7.172 | Half-life (T1/2): | 0.311 |
hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.367 |
Drug-inuced Liver Injury (DILI): | 0.064 | AMES Toxicity: | 0.071 |
Rat Oral Acute Toxicity: | 0.829 | Maximum Recommended Daily Dose: | 0.308 |
Skin Sensitization: | 0.809 | Carcinogencity: | 0.91 |
Eye Corrosion: | 0.309 | Eye Irritation: | 0.105 |
Respiratory Toxicity: | 0.982 |